Pluri (PLUR) Capital Expenditures Growth (1y) (2011 - 2025)
Pluri (PLUR) Capital Expenditures Growth (1y) (2011 - 2025) Analysis & Trends
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -22.99% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.68% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1,133.33% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -37.81% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 142.64% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.37% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -73.62% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 22,433.30% |
| 10 | Pluri | 16.21 Mn | 3.72 Mn | 86,000.00 | 299.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 299.11% |
| Sep 30, 2025 | -44.23% |
| Jun 30, 2025 | 7,110.00% |
| Mar 31, 2025 | 548.31% |
| Dec 31, 2024 | -7.44% |
| Sep 30, 2024 | 101.94% |
| Jun 30, 2024 | -89.69% |
| Mar 31, 2024 | 270.83% |
| Dec 31, 2023 | 77.94% |
| Sep 30, 2023 | 41.10% |
| Jun 30, 2023 | -51.26% |
| Mar 31, 2023 | -35.14% |
| Dec 31, 2022 | 134.48% |
| Sep 30, 2022 | 386.67% |
| Jun 30, 2022 | 373.81% |
| Mar 31, 2022 | -70.16% |
| Dec 31, 2021 | -77.69% |
| Sep 30, 2021 | -80.52% |
| Jun 30, 2021 | -80.73% |
| Mar 31, 2021 | 181.82% |